跳至主要内容
临床试验/NCT05723315
NCT05723315尚未招募不适用

Effect of rhBNP on Coronary Microcirculation in Patients With Acute ST-segment Elevation Myocardial Infarction After Primary PCI

Henan Institute of Cardiovascular Epidemiology0 个研究点目标入组 160 人开始时间: 2023年2月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
160
主要终点
MVO/LV(%)

研究概览

简要总结

The target population of this interventional study was STEMI patients. Primary discussion: Early rhBNP reduces microcirculation obstruction in STEMI patients undergoing primary PCI

详细描述

Direct percutaneous coronary intervention is the preferred reperfusion strategy for acute ST-segment elevation myocardial infarction. During the opening of infarct-related vessels, 5%-50% of patients showed slow flow or no reflow and other coronary microcirculation dysfunction, which aggravated myocardial injury and increased the incidence and mortality of heart failure. Studies have shown that recombinant human brain natriuretic peptide (rhBNP) can reduce reperfusion injury and reduce myocardial infarction area CMD. Prolonged ischemia leads to rapid depletion of intracellular ATP and tissue metabolic acidosis. Blood flow irrigation during reperfusion leads to decreased levels of ATP precursors, calcium overload in mitochondria, release of a large number of inflammatory factors and oxygen free radicals, which can lead to injury or death of myocardial and endothelial cells. rhBNP can enhance the activity of antioxidant enzymes, reduce the irreversible oxidative damage caused by free radicals to myocardium, reduce the myocardial infarction area during ischemia reperfusion, and may reduce the reperfusion injury and protect the viable myocardium.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • PPCI within 24 hours of symptom onset
  • Target vessel QFR-MR>250mm Hg*s/m

排除标准

  • claustrophobia
  • Postoperative TIMI grade 0-1
  • Pregnancy

研究组 & 干预措施

Experimental Group 1

Experimental

The experimental group was given neoptin within 3h after PCI for 72 hours (first at 1.5μg /kg intravenous load, then at 0.015μg /kg/min).

干预措施: recombinant human B-type natriuretic peptide (Drug)

结局指标

主要结局

MVO/LV(%)

时间窗: 3-14 days after PPCI

Microvascular obstruction assessed by magnetic resonance imaging

次要结局

  • MVO/LV(%)(30±7 days after PPCI)
  • MACCEs(7days,30days,3months,6 months)
  • LVEDV(ml)(3-14 days and 90±7 days after PPCI)
  • Troponin (highest value)(3-14 days after PPCI)
  • LGE/LV(%)(3-14 days and 90±7 days after PPCI)
  • IMH(3-14 days after PPCI)
  • LVESV(ml)(3-14 days and 90±7 days after PPCI)

研究者

发起方
Henan Institute of Cardiovascular Epidemiology
申办方类型
Other
责任方
Sponsor

相似试验

Effect of rhBNP on CMD in Patients With STEMI After... | 临床试验